SUNLENCA® Has a Demonstrated Safety and Tolerability Profile Through Week 52 in the CAPELLA Clinical Trial1,2
Adverse Reactions (All Grades) Reported in ≥3% of HTE Adults With HIV-1 Receiving SUNLENCA Through Week 52 (N=72)1
- Injection site reactions reported in >1% of patients were swelling (36%), pain (31%), erythema (31%), nodule (25%), induration (15%), pruritus (6%), extravasation (3%), and mass (3%). Injection site reactions reported in 1% of patients included discomfort, hematoma, edema, and ulcer1
- The median time to resolution of all injection site reactions excluding nodules and indurations was 5 days1,*
- Most injection site reactions were mild (Grade 1, 44%) or moderate (Grade 2, 17%)1
- Four percent of patients experienced a severe (Grade 3) injection site reaction (erythema, pain, swelling) that resolved within 15 days1
- One patient discontinued SUNLENCA at Week 52 due to an injection site nodule (Grade 1)1,2,†
The range of all injection site reactions was 1 to 183 days. The median time to resolution of nodules and indurations was 148 (range: 41 to 727) and 70 (range: 3 to 252) days, respectively.1 When reported, nodules and indurations were palpable but not visible and were approximately 1 to 4 cm in size. Qualitative descriptions were not routinely reported, nor were measurements routinely performed or standardized.1
No patients who received
SUNLENCA experienced a
study drug–related serious
adverse event or death
through week 52 (N=72)2,3
For illustrative purposes only. Not actual patient.